ConductScience.org, home
A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
API referenceFor AI assistants

Trial · NCT01296555

Participant flow87

How many started, completed or left each group, period by period.

1 to 20 of 87

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDPhase I, Stage 1: GDC-0032 3 Milligrams (mg) Once6
Overall StudySTARTEDPhase I, Stage 1: GDC-0032 5 mg QD3
Overall StudySTARTEDPhase I, Stage 1: GDC-0032 8 mg QD4
Overall StudySTARTEDPhase I, Stage 1: GDC-0032 12 mg QD10
Overall StudySTARTEDPhase I, Stage 1: GDC-0032 16 mg QD11
Overall StudySTARTEDPhase I, Stage 2: Cohort A - GDC-0032 9 mg QD20
Overall StudySTARTEDPhase I, Stage 2: Cohort B - GDC-0032 9 mg QD20
Overall StudySTARTEDPhase I, Stage 2: Cohort C - GDC-0032 9 mg QD + Midazolam 5 mg13
Overall StudySTARTEDPhase I, Stage 2: Cohort D - GDC-0032 9 mg QD10
Overall StudySTARTEDPhase I, Stage 2: Cohort E - GDC-0032 6 mg QD + Letrozole 2.5 mg QD20
Overall StudySTARTEDPhase I, Stage 2: Cohort E - GDC-0032 9 mg QD + Letrozole 2.5 mg QD8
Overall StudySTARTEDPhase I, Stage 2: Cohort F - GDC-0032 6 mg QD + Fulvestran t 500 mg21
Overall StudySTARTEDPhase I, Stage 2: Cohort F - GDC-0032 9 mg QD + Fulvestran t 500 mg6
Overall StudySTARTEDPhase I, Stage 2: Cohort G - GDC-0032 9 mg QD21
Overall StudySTARTEDPhase I, Stage 2: Cohort H - GDC-0032 6 mg QD35
Overall StudySTARTEDPhase I, Stage 2: Cohort J - GDC-0032 4 mg + Fulvestrant 500 mg20
Overall StudySTARTEDPhase I, Stage 2: Cohort K - GDC-0032 4 mg + Fulvestrant 500 mg20
Overall StudySTARTEDPhase I, Stage 2: Cohort L - GDC-0032 4 mg + Fulvestrant 500 mg19
Overall StudySTARTEDPhase I, Stage 2: Cohort M - GDC-0032 2 mg QD + Fulvestrant 500 mg20
Overall StudySTARTEDPhase I, Stage 2: Cohort N - GDC-0032 2 mg QD + Letrozole 2.5 mg QD27

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01296555/flow

API referenceFor AI assistants